stockportfolio.pro
Ovid Therapeutics Inc. (OVID)
Healthcare · Biotechnology · NasdaqCM
Ovid Therapeutics Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $12.62M | $208.38M | $1.50M | $392,000 | $566,000 | $7.25M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-22.41M | $-64.81M | $-51.98M | $-60.46M | $-81.04M | $122.83M | $-54.17M | $-52.34M | $-26.43M | $-17.41M |
| Net margin | — | — | — | — | -642.3% | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
Source: Ovid Therapeutics Inc. SEC filings (10-K). 11 years of history available in the interactive view.
Explore 11 years of Ovid Therapeutics Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OVID in your portfolio →
Ovid Therapeutics Inc. financial history by metric
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc. — frequently asked questions
What is Ovid Therapeutics Inc.'s revenue?
Ovid Therapeutics Inc. (OVID) reported revenue of $7.25M for fiscal year 2025, up 1181.3% from the prior year, according to its SEC filings.
Is Ovid Therapeutics Inc. profitable?
No — OVID reported a net loss of $-17.41M in fiscal 2025.
What is OVID's P/E ratio?
Ovid Therapeutics Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Ovid Therapeutics Inc. growing?
OVID's revenue grew at roughly -10.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ovid Therapeutics Inc. have?
As of fiscal year 2025, OVID carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ovid Therapeutics Inc.'s market cap?
Ovid Therapeutics Inc. (OVID) has a market capitalization of about $422.74M, based on the latest data in our nightly-refreshed cache.
When does Ovid Therapeutics Inc.'s fiscal year end?
OVID's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Ovid Therapeutics Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.